Alectinib
Treatment for Tracheal Bronchus And Lung Cancer
Typical Dosage: 600 mg orally twice daily
Effectiveness
88%
Safety Score
32%
Clinical Trials
200
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
32
DangerousModerateSafe
Treatment Details
Dosage Range
600 mg orally twice daily
Time to Effect
6-8 weeks
Treatment Duration
Until disease progression or unacceptable toxicity
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$185,000
Monitoring:$7,000
Side Effect Mgmt:$5,000
Total Annual:$197,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$250,000/QALY
QALYs Gained
0.76
Outcome-Based Costs
Cost per Responder
$262,667
Cost per Remission
$4,925,000
Comparison vs Crizotinib
Cost Difference
+$35,000/year
More expensive
QALY Difference
+0.76 QALYs
Better outcomes
Dominance
No dominance
Alectinib Outcomes
for Tracheal Bronchus And Lung Cancer
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+75%
Remission Rate
+4%
Common Side Effects
Fatigue
+50%
Myalgia
+40%
Edema
+40%
Anemia
+30%
Constipation
+30%
Liver enzyme elevation
+20%
Bradycardia
+15%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov